NCT03142334, Pembrolizumab, karsinoma sél ginjal

Pembrolizumab disatujuan pikeun pengobatan adjuvant karsinoma sél ginjal

Jan 2022: Pembrolizumab (Keytruda, Merck) parantos disatujuan ku Administrasi Pangan sareng Narkoba pikeun pengobatan adjuvant pasien kalayan karsinoma sél ginjal (RCC) anu aya dina résiko sedeng atanapi luhur kambuh saatos ..

KEYTRUDA, Lenvatinib, Lenvatinib ditambah pembrolizumab, Lenvima, Merck, karsinoma sél ginjal

FDA parantos nyatujuan kombinasi lenvatinib sareng pembrolizumab pikeun karsinoma sél ginjal anu maju

Agustus 2021: Kombinasi lenvatinib (Lenvima, Eisai) sareng pembrolizumab (Keytruda, Merck) parantos disahkeun ku Administrasi Pangan sareng Narkoba kanggo pangobatan lini penderita sawawa anu maju ku karsinom sél ginjal maju ..

Farmasi AVEO, Fotivda, panghambat kinase, karsinoma sél ginjal maju réfraktori, karsinoma sél ginjal, tivozanib

Tivozanib parantos disahkeun ku FDA pikeun pengobatan karsinoma sél ginjal anu maju deui atanapi réfraktor

Agustus 2021: Tivozanib (Fotivda, AVEO Farmasi, Inc.), penghambat kinase, parantos disahkeun ku FDA pikeun penderita sawawa kalayan karsinoma sél ginjal maju (RCC) saatos dua atanapi langkung ..

8 panyabab utama kanker ginjal

Many patients with kidney cancer do not know why they have this disease, meaning the causes of kidney cancer are relatively unknown. After the examination, they will be very surprised. Some even feel that the kidney is not a probl..